Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
The DOI matches its Crossref record; 132 of the 135 references it cites were found in a registry or an index.
Abstract
The concurrence of visceral obesity, insulin resistance and dyslipidaemia comprises the concept of the metabolic syndrome. The metabolic syndrome is an escalating problem in developed and developing societies that tracks with the obesity epidemic. Dyslipidaemia in the metabolic syndrome is potently atherogenic and, hence, is a major risk factor for CVD (cardiovascular disease) in these subjects. It is globally characterized by hypertriglyceridaemia, near normal LDL (low-density lipoprotein)-cholesterol and low plasma HDL (high-density lipoprotein)-cholesterol. ApoC-III (apolipoprotein C-III), an important regulator of lipoprotein metabolism, is strongly associated with hypertriglyceridaemia and the progression of CVD. ApoC-III impairs the lipolysis of TRLs [triacylglycerol (triglyceride)-rich lipoproteins] by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors. In the circulation, apoC-III is associated with TRLs and HDL, and freely exchanges among these lipoprotein particle systems. However, to fully understand the complex physiology and pathophysiology requires the application of tracer methodology and mathematical modelling. In addition, experimental evidence shows that apoC-III may also have a direct role in atherosclerosis. In the metabolic syndrome, increased apoC-III concentration, resulting from hepatic overproduction of VLDL (very-LDL) apoC-III, is strongly associated with delayed catabolism of triacylglycerols and TRLs. Several therapies pertinent to the metabolic syndrome, such as PPAR (peroxisome-proliferator-activated receptor) agonists and statins, can regulate apoC-III transport in the metabolic syndrome. Regulating apoC-III metabolism may be an important new therapeutic approach to managing dyslipidaemia and CVD risk in the metabolic syndrome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“High ApoC-III levels were shown to increase total triglyceride levels by an accumulation of VLDL and chylomicrons [166–169]”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [168]
In the citing paper
“In hypertriglyceridemia, more VLDL particles, as measured by apoB, and larger and more triglyceride-and apoC-III-enriched lipoproteins are found (39,64,65).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [65]
In the citing paper
“Clearance of VLDL from the circulation is reduced in many patients with hypertriglyceridemia (64, 65, 73), in part due to saturation of triglyceride clearance (74).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [65]
In the citing paper
“Consequently, APOC-III is considered an independent risk factor for cardiovascular disease [30, 31].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [31]
In the citing paper
“In contrast, apo C-III is an inhibitor of LPL, but also of hepatic lipase. Plasma apo C-III concentrations correlate positively with plasma TG [19].”
From Dyslipidemia in obesity: Mechanisms and potential targets (2013) · cites this paper as [19]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Insulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,358
Schoonjans, K., Staels, B., & Auwerx, J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42003-6 · Cited by 1,216
Identification of a nuclear receptor that is activated by farnesol metabolites
Forman, B. M., Goode, E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Lamph, W. W., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90530-8 · Cited by 1,210
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect
Tunaru, S., Kero, J., Schaub, A., Wufka, C., Blaukat, A., Pfeffer, K., & Offermanns, S. (2003) · Nature Medicine · doi:10.1038/nm824 · Cited by 791
The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)
Garcia-Calvo, M., Lisnock, J., Bull, H. G., Hawes, B. E., Burnett, D. A., Braun, M. P., Crona, J. H., Davis, H. R., Dean, D. C., Detmers, P. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500269102 · Cited by 670
Research works printed but not linked: 4
- Assmann, 1998, The emergence of triglycerides as a significant independent risk factor in coronary artery disease, Eur. Heart J., 19, M8
- Ginsberg, 1986, Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceriderich lipoproteins by lipoprotein lipase in vivo, J. Clin. Invest., 78, 1287, 10.1172/JCI112713 · DOI · Paper page
- Sundaram, 2007, New insights into the roles of apolipoprotein C-III in stimulating the production of hepatic VLDL, Arteriosclerosis Thrombosis Vascular Biology Annual Conference, P142
- Clavey, 1995, Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII and E, Arterioscler. Thromb. Vasc. Biol., 15, 963, 10.1161/01.ATV.15.7.963 · DOI · Paper page
Cited by
Items 201–282 of 282
Apolipoprotein-defined and NMR lipoprotein subclasses in the Veterans Affairs Diabetes Trial
Azar, M., Lyons, T. J., Alaupovic, P., Stoner, J. A., Quiroga, C., Kaufman, D., Lopes-Virella, M. F., Klein, R. L., & Jenkins, A. J. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.05.005 · Cited by 6
Wieczorek, E., Ćwiklińska, A., Kuchta, A., Kortas‐Stempak, B., Gliwińska, A., & Jankowski, M. (2021) · Nutrients · doi:10.3390/nu13041224 · Cited by 7
“The development of HTG can be related to genetic predisposition [6], excessive synthesis, and secretion of TG-rich lipoproteins (TRL), including chylomicron (CM) and very-low-density lipoprotein (VLDL) [7], and/or to impaired TRL clearance from plasma [8,9].”
BackgroundThe Essence of Lipoproteins in Cardiovascular Health and Diseases Treated by Photodynamic Therapy
Wańczura, P. M., Aebisher, D., Iwański, M. A., Myśliwiec, A., Dynarowicz, K., & Bartusik‐Aebisher, D. (2024) · Biomedicines · doi:10.3390/biomedicines12050961 · Cited by 5
“It binds to lipoproteins that contain ApoB or ApoA, including chylomicrons, residues of VLDL particles, intermediate-density lipoproteins (IDL), LDL, and HDL [127].”
BackgroundAPOC3: Triglycerides do matter
Hassan, M. S. (2014) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2014.38 · Cited by 5
“In addition, the use of statins, thiazolidinediones, ezetimibe, niacin, fish oil and weight loss, has been associated with decreases in plasma APOC3 levels.(14) In the same context, Kathiresan et al.”
BackgroundUpdate on medical management of dyslipidemia and atherosclerosis
GINTER, E., & Simko, V. (2013) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2013_054 · Cited by 5
“Recent data suggest that loss of function mutations within the apoC-III gene lowers the TG levels (53).”
Analysis of N‐ and O‐linked protein glycosylation in children with Prader‐Willi syndrome
Munce, T., Heussler, H., & Bowling, F. G. (2010) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2010.01323.x · Cited by 5
Volta, A., Hovingh, G. K., & Grefhorst, A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000489 · Cited by 5
CD14+-Monocytes Exposed to Apolipoprotein CIII Express Tissue Factor
Olivieri, O., Gasperini, S., Calzetti, F., Gardiman, E., Castagna, A., Martinelli, N., Tamassia, N., & Cassatella, M. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032223 · Cited by 6
“ApoCIII is also recognized as an important risk factor for ischemic heart disease [1,2] and for the development of atherosclerotic disease [3].”
BackgroundCorella, D. (2008) · Grasas y Aceites · doi:10.3989/gya.086408 · Cited by 5
Chevalier, C., Oliveira, A. R., Blanchard, V., May, C. L., Cariou, B., Hadjadj, S., & Croyal, M. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101683 · Cited by 6
Maffeis, C., Bonadonna, R. C., Maschio, M., Aiello, G., Tommasi, M., Marigliano, M., Fornari, E., & Morandi, A. (2013) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2013.86 · Cited by 5
Alireza, H. (2021) · International Journal of Membrane Science and Technology · doi:10.15379/2410-1869.2021.08.02.05 · Cited by 5
Hlaing, E. E., Rungcharoenarrichit, S., Lailerd, N., Roytrakul, S., & Piamrojanaphat, P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814466-4.00025-2 · Cited by 5
den Hollander, B., Brands, M. M. M. G., Nijhuis, I. J. M., van Troostwijk, L. J. A. E. D., van Essen, P., Hofsteenge, G. H., Koot, B. G. P., Müller, A. R., Tseng, L. A., Stroes, E. S. G., et al. (2024) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2024.108347 · Cited by 4
Ballantyne, C. M., Baass, A. W., Rosenson, R. S., Hegele, R. A., Nicholls, S. J., Vasas, S., Clifton, P. M., Lucas, K. J., Páll, D., Zhou, R., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101523 · Cited by 3
“These reductions were driven by continuous reductions in APOC3 levels to (cid:0) 79 % [16.5] at Month 12 and (cid:0) 81 % [15.9] at Month 24 (Table 2.”
InfluentialSelf-citationHan, Y., Qi, R., & Liu, C. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.147 · Cited by 3
“ApoCIII is mainly distributed in ApoB containing lipoproteins and HDL, accounting for about 50% of protein components in VLDL and 2% in HDL, and it quickly shifts between these particles [9].”
Apolipoprotein C-III Nanodiscs Studied by Site-Specific Tryptophan Fluorescence
Brisbois, C. A., & Lee, J. C. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00599 · Cited by 3
Alireza, H. (2021) · International Journal of Membrane Science and Technology · doi:10.15379/2410-1869.2021.08.02.04 · Cited by 3
Calcaterra, I. L., Santoro, R., Vitelli, N., Cirillo, F., D’Errico, G., Guerrino, C., Cardiero, G., Taranto, M. D. D., Fortunato, G., Iannuzzo, G., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092017 · Cited by 3
“Although available lipid-lowering therapies (fibrates, statins and omega-3 fatty acids) decrease serum triglycerides [2,3], a non-negligible percentage of subjects with hypertriglyceridemia (HTG), particularly those with FCS, do not achieve therapeutic goals [4].”
BackgroundGhattas, M. H., Badawy, H. K., Mesbah, N. M., & Abo–Elmatty, D. M. (2013) · Cited by 3
Cytotoxic effects of conjugated linoleic acids on human hepatoma cancer cells (HepG2)
Melaku, A., Kadir, A. A., Othman, F., Meng, G., & Sazili, A. Q. (2012) · Journal of Molecular Pathophysiology · doi:10.5455/jmp.20120127120302 · Cited by 4
Production and Metabolism of Triglyceride-Rich Lipoproteins: Impact of Diabetes
Pirillo, A., Norata, G. D., & Catapano, A. L. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_7 · Cited by 3
Current developments in lipid-lowering therapy for the patient with chronic kidney disease
Burnhope, E., Green, D., Kalra, P. A., & Kalra, P. R. (2011) · Clinical Lipidology · doi:10.2217/clp.11.61 · Cited by 2
Gaudet, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00035-2 · Cited by 2
Human apolipoprotein CIII levels; evaluation of three assay methods
Sandin, Å., Olofsson, C., Strålfors, A., Ekberg, N. R., Brismar, K., Juntti‐Berggren, L., & Eggertsen, G. (2020) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2020.1725976 · Cited by 2
Valéro, R. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.06.013 · Cited by 2
Efficacy and safety of olezarsen in patients with vs without baseline fibrate use
Wang, A. Z., Alexander, V. J., Prohaska, T. A., Ran, X., Goodrich, E. L., Murphy, S. A., Zimerman, A., Moura, F. A., Kang, Y. M., Nordestgaard, B. G., et al. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.08.001 · Cited by 1
Obregón, O., Aure, G., Amaiz, M. L., Castro, J., & Brito, S. (2024) · Revista Científica CMDLT · doi:10.55361/cmdlt.v17i1.276 · Cited by 1
Hypertriglyceridemia: diagnostic issues, therapeutic strategies
Bakaleiko, V. V., Reutova, O. V., Алиева, М. С., Baratashvili, G. G., Kostareva, A. A., & Alieva, A. S. (2024) · Russian Journal for Personalized Medicine · doi:10.18705/2782-3806-20244-3-194-205 · Cited by 1
Contribución de la apolipoproteína CIII a la aterogenicidad de las dislipidemias
Camejo, G., & Davidsson, P. (2012) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2012.02.006 · Cited by 2
Chen, H., Wu, M., Jiang, W., Liu, X., Zhang, J., & Yu, C. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4472 · Cited by 1
Meisenberg, G., & Simmons, W. H. (2012) · Elsevier eBooks · doi:10.1016/b978-0-323-07155-0.00025-3 · Cited by 1
Ooi, E. M. M., & Watts, G. F. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32831b6d38 · Cited by 1
Self-citationHumoral response towards high density lipoprotein : a new mechanism for atherogenesis
Batuca, J. R. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 2
Apolipoprotein CIII and Ljungan virus in diabetes
Holmberg, R. (2010) · Figshare
Nutritional management of cardiovascular disease in the near future
Martín, A. Á. (2013) · Universidad Industrial de Santander
Concentraciones de apolipoproteína C-III y E en individuos con lesión aterosclerótica coronaria
Aguilar, D., Amuchástegui, M. V. M., Bañares, V. G., Peterson, G., & Tavella, M. J. (2010) · Americanae (AECID Library)
Examining controversies and new frontiers in lipid management
Nicholls, S. J. (2014) · Clinical Lipidology · doi:10.2217/clp.14.38
BIOACTIVE FATTY ACID SUPPLEMENTATION AND RISK FACTORS FOR THE METABOLIC SYNDROME
Mitchell, P. L. (2010) · Library and Archives Canada (Government of Canada)
Altered metabolism of apolipoprotein C.III: a contributor in chronic kidney disease?
Ooi, E. M. M., Watts, G. F., & Barrett, P. H. R. (2011) · Clinical Lipidology · doi:10.2217/clp.11.18
Self-citationNovel factors affecting clearance of triacylglycerol-rich lipoproteins from blood
Nilsson, S. K. (2010)
Identification of proteins associated with pediatric bilateral Wilms tumor
Yan, Z., Meng, Q., Yang, J., Zhang, J., Zhao, W., Guo, F., Song, D., Zhan, Y., Fan, D., Zhou, R., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.5306
“…and functional decline, resulting in excessive high concentrations of cholesterol and insulin in blood not excluding raised level of APO C‑Ⅲ expression due to stronger exuberance of metabolic activities of tumor tissues than other tissues, and it has no clear causality with BWT development (14).”
West, G. (2017) · OpenCommons - UConn (University of Connecticut)
Lemmens, C. (2016) · MaRBLe · doi:10.26481/marble.2014.v2.310
“Reducing these levels is an important objective in controlling CVD. Dietary components can be used as a strategy against dyslipidemia.”
BackgroundInfluentialCheng, S., Pang, B., Gu, C., Sun, S., An, C., Zhang, Z., Li, J., & Liu, G.-J. (2017) · Frontiers in Laboratory Medicine · doi:10.1016/j.flm.2017.10.002
VII. Triglyceride and HDL Cholesterol as Risk Factors and the Treatment Targets for Atherosclerosis
Ai, M. (2017) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.106.725
Rodriguez‐Dimitrescu, C. (2012) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3v913
Åvall, K., Berggren, P., & Juntti‐Berggren, L. (2018) · Laboratory Animal Research · doi:10.5625/lar.2018.34.3.126
“It has for example been shown that red wine rich in polyphenols with and without alcohol improves insulin sensitivity and activates anti-inflammatory and anti-oxidant processes with positive effects on CVD [27,28].”
BackgroundInfluentialDissecting the role of apolipoprotein CIII in diabetic wound healing
Cho, M. M. W. (2019) · doi:10.32657/10220/48515 · Cited by 1
Clinical Biomarkers of Dyslipidemia
Park, H.-K. (2021) · Stroke revisited · doi:10.1007/978-981-16-3923-4_5
Lipoprotein Metabolism and the Treatment of Lipid Disorders
Freeman, M. W. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00042-3
Zylbeari, L., Haxhirexha, K., Behxheti, N., Haxhirexha, F. D., Zylbeari, G., Bexheti, Z., Alimani, J. J., Ahmeti, S. L., Qalili, A., & Lika, H. (2018) · Albanian Journal of Trauma and Emergency Surgery · doi:10.32391/ajtes.v2i2.15
Chemical constituents of fan-si abutilon indicum stems
Widyasti, A. R. (2021) · Chula Digiverse · doi:10.58837/chula.the.2021.63
Hernández, L. K., Guerra, G. A., Gordillo, G. C., Parreño, J. M., Solano, G., Flores, J. M., León, E., Campos, A. B., & Guerra, A. (2023) · Ciencia e Investigación · doi:10.15381/ci.v26i1.27489
Singh, H., Shyamveer, Jori, C., Mahajan, S. D., Aalinkeel, R., Kaliyappan, K., Bhattacharya, M., Parvez, M. K., & Al-Dosari, M. S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30519
Apolipoproteins and cardiovascular diseases
Kaur, A., Saha, S., Ujjainiya, R., Ray, A., Basak, T., & Sengupta, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19116-9.00032-4
Development and validation of a nomogram model for predicting postprandial hypertriglyceridemia
Gu, W., Shi, L., Li, X., Zheng, K., & Song, G. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1622385
Chackathayil, J. (2013) · University of Birmingham Institutional Research Archive (University of Birmingham)
Chen, H., Zhou, X., Hu, J., Li, S., Wang, Z., Zhu, T., Cheng, H., & Zhang, G. (2023) · Figshare · doi:10.6084/m9.figshare.24792259
Chen, H., Zhou, X., Hu, J., Li, S., Wang, Z., Zhu, T., Cheng, H., & Zhang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26652357
Chen, H., Zhou, X., Hu, J., Li, S., Wang, Z., Zhu, T., Cheng, H., & Zhang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26652360
Sandholm, N., Hotakainen, R., Haukka, J. K., Sigfrids, F. J., Dahlström, E. H., Antikainen, A. A., Valo, E., Syreeni, A., Kilpeläinen, E., Kytölä, A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21622433
Chen, H., Zhou, X., Hu, J., Li, S., Wang, Z., Zhu, T., Cheng, H., & Zhang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26652363
Chen, H., Zhou, X., Hu, J., Li, S., Wang, Z., Zhu, T., Cheng, H., & Zhang, G. (2024) · Figshare · doi:10.6084/m9.figshare.24792442
Katzmann, J. L., Werner, C. M., Stojaković, T., März, W., Scharnagl, H., & Laufs, U. (2020) · Figshare · doi:10.6084/m9.figshare.12401108
Katzmann, J. L., Werner, C. M., Stojaković, T., März, W., Scharnagl, H., & Laufs, U. (2020) · Figshare · doi:10.6084/m9.figshare.12401099
Ahmad, C. M., Kastle, R.-A., Patel, H., Haberman, S. R., & Youkhana, M. (2026) · Cureus · doi:10.7759/cureus.105594
“APOC3 is located on triglyceride-rich lipoproteins and can inhibit LPL, block hepatic uptake, and promote inflammation, contributing to hypertriglyceridemia [13].”
Elkina, A. Y., Shvarts, Y. G., Kiselev, A. R., & Акимова, Н. С. (2026) · Current Hypertension Reviews · doi:10.2174/0115734021428732251226052716
Atherogenic apolipoprotein C-III may not be as bad as we thought
Smith, A. N., Zhang, Z., & Zheng, Z. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.02.023
Kotlyarov, S. N., Котлярова, А. А., Catanzaro, R., & Marotta, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198614
Dupree, E. J., Holsen, T. M., Pagano, J. J., Darie, C. C., & Crimmins, B. S. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-29437-1_18
The effect of oligomeric procyanidins on endothelial function and cholesterol homeostasis
Rull, G. (2012) · OpenGrey (Institut de l'Information Scientifique et Technique)
Metadata
- Authors
- Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F.
- Affiliations
- The University of Western Australia (AU)
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2008-04-14
- Volume
- 114
- Issue
- 10
- Pages
- 611-624
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2037283919
- Cited by
- 282
- References
- 135
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 12 · 2023: 11 · 2022: 12 · 2021: 16 · 2020: 18 · 2019: 22 · 2018: 16 · 2017: 16 · 2016: 25 · 2015: 18 · 2014: 17 · 2013: 25 · 2012: 10
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Funders
- National Institute of Biomedical Imaging and Bioengineering (P41EB001975)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, metabolic syndrome, hypertriglyceridemia, dyslipidemia, cardiovascular risk, triglyceride-rich lipoproteins, lipoprotein lipase inhibition, atherosclerosis, PPAR agonists, statins, lipoprotein metabolism
- MeSH terms
- Animals, Humans, Insulin Resistance, Intestinal Mucosa, Liver, Risk Factors, Triglycerides, Hypertriglyceridemia, Metabolic Syndrome, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.